---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-031324"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T16:22:10.231852+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation highlighting pipeline progress and clinical data

## Summary
- [212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors shows anti-tumor activity with no renal decline.
- Melanoma program [212Pb]VMT01 Phase 1/2a ongoing; safety profile detailed in presentation.
- PSV359 targeting FAP-α active on tumor and stroma; pre-targeting platform also described.
- On-demand order fulfillment at regional sites as part of supply chain and manufacturing infrastructure.

## SEC filing metadata
- accession: 0000950170-25-031324
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025031324/0000950170-25-031324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025031324/catx-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-031324
- JSON: https://secwatch.observer/filing/0000950170-25-031324.json
- Plain text: https://secwatch.observer/filing/0000950170-25-031324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.